Oral JAK1 drug clears phase 3 hurdle for a painful skin disease

Two phase 3 trials of povorcitinib report positive results for hidradenitis suppurativa, an underserved chronic skin condition.

Two randomized, double-blind, placebo-controlled phase 3 trials — labeled STOP-HS1 and STOP-HS2 — have reported positive results for povorcitinib, an oral JAK1 inhibitor being developed for hidradenitis suppurativa. The findings were published in Nature Medicine.

Hidradenitis suppurativa is a painful, recurring inflammatory skin disease that has long had few effective treatment options. An oral drug matters here because pills are simpler to distribute, store, and take than many injectable or infused therapies, which lowers the practical barrier to treatment.

If the drug is approved and reaches the market, it would add a treatment option for a condition that has been comparatively neglected. That is the abundance angle: more approved therapies for an underserved disease tends to expand who can actually get treated, especially as competition eventually pressures price.

The caveat is that positive phase 3 data is a milestone, not a shipping product. We are working only from the study description, without access to the underlying trial numbers, so the size of the benefit, safety profile, and eventual pricing all remain open. Regulatory review and approval decisions would come next, and access will depend on how the drug is priced and covered.

Source: Nature Medicine